Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.41 |
| ▸ | HTR3B | O95264 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985666 | 0.85 | — | — | |
| SCHEMBL3302046 | 0.81 | CHKA (0.32) | — | |
| SCHEMBL4510267 | 0.78 | LMNA (0.42) | — | |
| SCHEMBL16816618 | 0.72 | SLC6A2 (0.36) | — | |
| SCHEMBL303465 | 0.65 | PLD1 (0.44) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4515850 | 0.65 | ADRB1 (0.44) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1606819 | 0.64 | ADRB1 (0.41) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL188699 | 0.64 | ADRB1 (0.50) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5570604 | 0.63 | ADRB1 (0.77) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17595113 | 0.62 | PLD1 (0.53) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458380-B1 | CIS-2,4,5- TRIPHENYL-IMIDAZOLINES AND THEIR USE IN THE TREATMENT OF TUMORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | claimed |
| US-7282594-B2 | Synthetic methodology for the reductive alkylation at the C-3 position of indoles | WYETH (US) | 2007-10-16 | — | — | US | claimed |
| EP-1458380-A1 | CIS-2,4,5- TRIPHENYL-IMIDAZOLINES AND THEIR USE IN THE TREATMENT OF TUMORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-22 | — | — | EP | claimed |
| WO-2003051359-A1 | CIS-2,4,5- TRIPHENYL-IMIDAZOLINES AND THEIR USE IN THE TREATMENT OF TUMORS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | claimed |
| EP-2903613-B1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9586948-B2 | Inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150274708-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2903613-A1 | INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014058691-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-1458380-B1 | CIS-2,4,5- TRIPHENYL-IMIDAZOLINES AND THEIR USE IN THE TREATMENT OF TUMORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20080009485-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis | WYETH (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009485-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis | PLA2G12A, PLA2G1B, PLA2G5 | ADRB1 2018/4885HTR3E 1356/4885HTR3B 779/4885 |
| US-20150274708-A1 | INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | ADRB1 1883/4885HTR3E 3819/4885HTR3B 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.